An interventional study of New Intervention form including and Standard treatment in Parkinson Disease, sponsored by Johannes Gutenberg University Mainz. Active, not recruiting at 2 sites in Germany. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Johannes Gutenberg University Mainz · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 263 studies in Parkinson Disease with a site in Germany — 41 open to participants now, 53 under way, 2 of them phase 3. Parkinson Disease · Germany.
Among the 263 studies in Parkinson Disease with a site in Germany, this one has the largest planned enrollment of the 198 interventional ones that give a count, is one of 15 that started in 2024, is one of 50 with no phase, reaches primary completion later than 14 of the 52 other live ones, and was the 235th registered.
4,576 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
Browse Parkinson Disease studies →41 of the 263 studies in Parkinson Disease with a site in Germany are open now. Recruiting first, the newest first:
University Hospital Tuebingen · Sites in Germany, France, Italy and 4 more countries
Ages 35–80
MODAG GmbH · Sites in Germany
Ages 50–75 · Healthy volunteers
H. Lundbeck A/S · Sites in Germany, United States, Czechia and 1 more country
Ages 40–85
University Hospital Muenster · Sites in Germany
Ages 18+
Integrative Research Laboratories AB · Sites in Germany, Bulgaria, Poland and 1 more country
Ages 50–90
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.
This study: 30 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
263 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 53 · Phase 3 65 · Phase 4 19
First in 2001; this study’s year is marked. 15 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,354 is above the median of 40 across 3,355 interventional studies indexed under Parkinson Disease.
Median enrollment 106 across the 198 interventional studies, 194 across the 63 observational. Of the 185 that completed or were terminated, 73 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
172 of 263 have an industry lead sponsor. The 10 most frequent:
Johannes Gutenberg University Mainz is the lead sponsor of 156 studies on the registry; 20 are open to participants now.
Johannes Gutenberg University Mainz has 2 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
15 of the studies in Parkinson Disease with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07134634Parkinson's Clinic in Beelitz-HeilstattenEffect of a Vibrating Therapy Ball on Tremor and Daily Activities in Patients With Different Tremor Syndroms | 2026-11 |
| NCT06580977Heidelberg UniversityExploring the Effects of Exercise on Memory and Cognition in Parkinson´s Disease | 2026-12 |
| NCT07141719University of KielCollection of Digital Parameters From Parts of the Neurological Examination Using an Eye Tracker | 2026-12-31 |
| NCT06602193Denali Therapeutics Inc.Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) | 2027-03 |
| NCT06993571Universitätsklinikum Hamburg-EppendorfCerebellar Transcranial Alternating Current Stimulation (tACS) to Modulate Parkinson's Disease Tremor | 2027-03-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 263 studies in Parkinson Disease with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Project objective: To improve the health care of Parkinson's disease patients in the ParkinsonNetz RheinMain+.
Hypothesis: Through the interdisciplinary and cross- sectoral networking in a tele medical network and the coordinating function of an "advanced practice nurse" (APN) specially trained for Parkinson's disease, the process quality within the network is increased and the individual health status is positively influenced.
To effectively influence the long-term course of Parkinson´s a synergistic application of an individualized therapy program, which is tailored specifically to the symptoms and disease stages, is needed. The central element of the new form of care is the implementation of a tele medical evaluation and coordination function, which controls individualized treatment processes within the network. The individualized evaluation and coordination of treatment paths is carried out within the already existing Parkinson's network RheinMain+ by a non-physician medical specialist (APN) specially trained for the indication Parkinson's disease. In-depth assessments of the individual disease situation of the patients will take place. Based on these assessments, an evidence-based and patient-centered treatment and care plan is developed. The treatment plans are monitored, controlled and evaluated by the APNs using audiovisual or tele medical communication. In addition, APNs are empowered to initiate treatment interventions necessary to implement clinical guidelines and standards, and to take charge of these interventions as part of delegation processes. The APNs ensure that patients are cared for in accordance with needs and guidelines in all areas of care. To this end, they offer, among other things, training in the handling of patients with Parkinson's disease for other professional groups involved in the treatment process and not only have the patients in mind, but also include relatives and the supporting team.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Severe dementia
tumor disease with limited , need for dialysis, etc.)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
New intervention form
Other: New Intervention form including
Standard treatment for Parkinson Disease
Other: Standard treatment
The central element of the new form of care is the implementation of a tele medical evaluation and coordination function, which controls individualized treatment processes within the network. The individualized evaluation and coordination of treatment paths is carried out within the already existing Parkinson's network RheinMain+ by a non-physician medical specialist (APN) specially trained for the indication Parkinson's disease.
The standard treatment which all compulsory insured patients get.
Are there differences in the change in Parkinson's-specific quality of life after 12 months of observation between the intervention group and the controll group- operationalized by the PDQ-39
Parkinson´s Disease Quetionnaire -39 - to measure the differences in the change in Parkinson's-specific quality of life after 12 months of observation between the intervention group and the control group
Time frame: duration of the intervention: 24 months
Are there differences in the change in motor symptoms after 12 months of observation between the intervention group and the control group measured with the MDS-Unified Parkinson's Disease Rating Scale part III (MDS-UPDRS III)
MDS-UPDRS III- to measure the differences in the change in motor symptoms after 12 months of observation between the intervention group and the control group
Time frame: duration of the intervention: 24 months
Are there differences in the change in quality of life across diseases after 12 months of observation between the intervention and the control group measured with the European Quality of Life 5 Dimensions 3 Level Version (EQ-5D-5L)
EQ-5D-5L- to measure the differences in the change in quality of life across diseases after 12 months of observation between the intervention group and the control group
Time frame: duration of the intervention: 24 months
Plan to share: No
Ran from Jul 2024 to primary completion in Oct 2026, 27 months.
Of 1,294 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's 27 months is above that.
Counting every sponsor, half of 1,370 studies reached it within 25 months; a quarter within 12 and three quarters within 44.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Oct 2025 → Oct 2026 and completion Jan 2027 → Jul 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Johannes Gutenberg University Mainz →